Hochhaus A, Saussele S, Baerlocher GM, Bruemmendorf TH, Burchert A, La Rosee P, Hasford J, Hehlmann R, Heim D, Krause S, Le Coutre P, Niederwieser D, Mayer J, Lange T, Haenel M, Stegelmann F, Gil A, Ernst T, Fabisch C, Pfirrmann M (2018)
Publication Type: Conference contribution
Publication year: 2018
Publisher: AMER SOC HEMATOLOGY
City/Town: WASHINGTON
Conference Proceedings Title: BLOOD
DOI: 10.1182/blood-2018-99-112119
APA:
Hochhaus, A., Saussele, S., Baerlocher, G.M., Bruemmendorf, T.H., Burchert, A., La Rosee, P.,... Pfirrmann, M. (2018). Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study. In BLOOD. San Diego, CA, US: WASHINGTON: AMER SOC HEMATOLOGY.
MLA:
Hochhaus, Andreas, et al. "Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study." Proceedings of the 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA WASHINGTON: AMER SOC HEMATOLOGY, 2018.
BibTeX: Download